The Director's Forum series is written and edited by Michael Sanborn and Robert Weber and is designed to guide pharmacy leaders in establishing patient-centered services in hospitals and health systems. Another specific goal of this column is to address many of the key challenges that pharmacy directors face today, while providing information to foster growth in pharmacy leadership and patient safety. This month's Forum focuses on developing a pharmacy-based investigational drug service in a hospital pharmacy department. As part of a patient-centered pharmacy department, a investigational drug service can significantly contribute to the research mission of a hospital.
Get full access to this article
View all access options for this article.
References
1.
KleinmanL.M., TangreaJ.A., GallelliJ.F.Control of investigational drugs in a research hospital. Am J Hosp Pharm.1974; 31(4): 368–371.
2.
KleinmanL.M., TangreaJ.A.Involvement of the hospital pharmacist in single- and double-blind studies. Am J Hosp Pharm.1974; 31(10): 979–981.
3.
PeltzmanS.An evaluation of consumer protection legislation: the 1962 drug amendments. J Polit Econ.1973;81(5): 1049–1091.
4.
LaFleurJ., TylerL.S., SharmaR.R.Economic benefits of investigational drug services at an academic institution. Am J Health Syst Pharm.2004; 61(1): 27–32.
5.
The Food and Drug Administration.Clinical testing for safe and effective drugs, DHEW Publication No. (FDA) 74-3015.US Government Printing Office, Washington, DC.
6.
AnsaniN., SirioC., HendersonB., SmithermanT., WeberR.J., SkledarS.J., ZgheibN, BranchR.A.Designing a strategy to promote safe innovative off-label use of medications. Am J of Med Qual.2006; 21: 246–254.
